EVis Bioscience Successfully Closes €740K Pre-Seed Round on Capital Cell
Campaign reaches 105.5% of target, strengthening EVis’s position in next-generation RNA therapeutics
EVis Bioscience AG has successfully closed its pre-seed funding round on Capital Cell, raising €740,000 and surpassing the original funding target at 105.5%.
The campaign attracted strong support from private and professional investors across Europe, reflecting growing confidence in EVis’s hybrid RNA delivery platform and its potential to advance targeted gene therapies.
A Strong Signal from the Market
Closing above target in a competitive biotech investment environment represents an important validation milestone. The Capital Cell campaign confirms:
- Market interest in next-generation RNA delivery technologies
- Confidence in EVis’s scientific and translational roadmap
- Recognition of the company’s differentiated hybrid extracellular vesicle platform
The funding round provides EVis with the resources to accelerate platform optimization, preclinical validation, and team expansion.
Strategic Momentum
The successful raise builds on recent institutional validation, including the CHF 311,000 non-dilutive grant awarded by Innosuisse for an 18-month preclinical program in collaboration with the University of Zurich.
Together, these milestones significantly reinforce EVis Bioscience’s scientific credibility and financial foundation.
Statement from Leadership
“The successful closure of our €740k pre-seed round on Capital Cell, reaching 105.5% of our target, represents a significant milestone for EVis Bioscience. We are grateful to our investors for their trust and support. Together with the backing of Innosuisse, we are now well positioned to advance our platform toward the next key stage of development.”
— Prof. Elita Montanari, CTO, acting CEO and co-founder of EVis Bioscience
Looking Ahead
With the pre-seed round successfully completed, EVis Bioscience is positioned to:
- Advance its hybrid RNA delivery platform
- Expand its scientific team
- Strengthen preclinical development programs
- Prepare for future strategic financing rounds
The company remains focused on delivering scalable, biologically aligned RNA therapeutics addressing areas of high unmet medical need.
👉 View the full campaign details on Capital Cell
